机译:非血清心房颤动患者口腔抗凝血剂的有效性和安全性鸟类研究
Univ Birmingham Inst Cardiovasc Sci Birmingham W Midlands England;
STATinMED Res Hlth Econ &
Outcomes Res Ann Arbor MI USA;
Bristol Myers Squibb Co Worldwide Hlth Econ &
Outcomes Res Lawrenceville NJ USA;
Bristol Myers Squibb Co Worldwide Hlth Econ &
Outcomes Res Lawrenceville NJ USA;
Pfizer Inc Patient Hlth &
Impact Outcomes &
Evidence New York NY USA;
Bristol Myers Squibb Co US Hlth Econ &
Outcomes Res Lawrenceville NJ USA;
Pfizer Inc Patient Hlth &
Impact Outcomes &
Evidence Groton CT 06340 USA;
Pfizer Inc Patient Hlth &
Impact Outcomes &
Evidence New York NY USA;
Bristol Myers Squibb Co Worldwide Med Lawrenceville NJ USA;
Bristol Myers Squibb Co US Hlth Econ &
Outcomes Res Lawrenceville NJ USA;
Bristol Myers Squibb Co Ctr Observat Res &
Data Sci Lawrenceville NJ USA;
Univ Michigan Dept Internal Med Ann Arbor MI 48109 USA;
Ochsner Clin Fdn Dept Hosp Med New Orleans LA USA;
anticoagulants; apixaban; dabigatran; hemorrhage; rivaroxaban; stroke; warfarin;
机译:Jayaraman等人关于文章,“患者缺血性脑卒中发病率较高,患有新的口腔抗凝剂的患者”和“非衰弱性心房颤动患者口腔抗凝血剂的有效性和安全性:鸟类研究”
机译:非血清心房颤动患者口腔抗凝血剂的有效性和安全性:鸟类研究(Vol 49,PG 2933,2018)
机译:非血清心房颤动患者口腔抗凝血剂的有效性和安全性鸟类研究
机译:心房颤动患者的口腔抗凝血剂自我管理:它有多效益和安全?
机译:在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
机译:纠正:非瓣膜性房颤患者口服抗凝药的有效性和安全性:ARISTOPHANES研究
机译:Jayaraman等人关于文章,“患者缺血性脑卒中发病率较高,患有新的口腔抗凝剂的患者”和“非衰弱性心房颤动患者口腔抗凝血剂的有效性和安全性:鸟类研究”